SI1805169T1 - Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe - Google Patents
Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabeInfo
- Publication number
- SI1805169T1 SI1805169T1 SI200530613T SI200530613T SI1805169T1 SI 1805169 T1 SI1805169 T1 SI 1805169T1 SI 200530613 T SI200530613 T SI 200530613T SI 200530613 T SI200530613 T SI 200530613T SI 1805169 T1 SI1805169 T1 SI 1805169T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds
- histamine
- preparation
- methods
- therapeutic uses
- Prior art date
Links
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61978504P | 2004-10-18 | 2004-10-18 | |
| EP05804419A EP1805169B1 (en) | 2004-10-18 | 2005-10-11 | Histamine h3 receptor inhibitors, their preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1805169T1 true SI1805169T1 (sl) | 2009-06-30 |
Family
ID=35677663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200530613T SI1805169T1 (sl) | 2004-10-18 | 2005-10-11 | Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7846950B2 (enExample) |
| EP (1) | EP1805169B1 (enExample) |
| JP (1) | JP5057982B2 (enExample) |
| AT (1) | ATE418553T1 (enExample) |
| CY (1) | CY1110453T1 (enExample) |
| DE (1) | DE602005011988D1 (enExample) |
| DK (1) | DK1805169T3 (enExample) |
| ES (1) | ES2318565T3 (enExample) |
| PL (1) | PL1805169T3 (enExample) |
| PT (1) | PT1805169E (enExample) |
| SI (1) | SI1805169T1 (enExample) |
| WO (1) | WO2006044228A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| CA2600757C (en) * | 2005-03-17 | 2014-02-18 | Eli Lilly And Company | Pyrrolidine derivatives as histamine h3 receptor antagonists |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| EA201291384A1 (ru) | 2010-07-06 | 2013-07-30 | Астразенека Аб | Терапевтические агенты 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2579596B1 (fr) | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| FR2671083B1 (fr) | 1990-12-31 | 1994-12-23 | Inst Nat Sante Rech Med | Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques. |
| AU721325B2 (en) | 1995-05-30 | 2000-06-29 | Gliatech Inc. | 1H-4(5)-substituted imidazole derivatives |
| US5652258A (en) | 1995-05-30 | 1997-07-29 | Gliatech, Inc. | 2-(4-imidazoyl) cyclopropyl derivatives |
| CA2244745A1 (en) | 1996-02-09 | 1997-08-14 | James Black Foundation Limited | Histamine h3 receptor ligands |
| EP1379493A2 (en) * | 2001-03-23 | 2004-01-14 | Eli Lilly and Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| US7696234B2 (en) * | 2004-06-02 | 2010-04-13 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
-
2005
- 2005-10-11 WO PCT/US2005/036023 patent/WO2006044228A1/en not_active Ceased
- 2005-10-11 JP JP2007536740A patent/JP5057982B2/ja not_active Expired - Fee Related
- 2005-10-11 US US11/577,388 patent/US7846950B2/en not_active Expired - Fee Related
- 2005-10-11 EP EP05804419A patent/EP1805169B1/en not_active Expired - Lifetime
- 2005-10-11 DE DE602005011988T patent/DE602005011988D1/de not_active Expired - Lifetime
- 2005-10-11 AT AT05804419T patent/ATE418553T1/de active
- 2005-10-11 ES ES05804419T patent/ES2318565T3/es not_active Expired - Lifetime
- 2005-10-11 PL PL05804419T patent/PL1805169T3/pl unknown
- 2005-10-11 DK DK05804419T patent/DK1805169T3/da active
- 2005-10-11 SI SI200530613T patent/SI1805169T1/sl unknown
- 2005-10-11 PT PT05804419T patent/PT1805169E/pt unknown
-
2009
- 2009-03-10 CY CY20091100269T patent/CY1110453T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1805169A1 (en) | 2007-07-11 |
| PL1805169T3 (pl) | 2009-05-29 |
| EP1805169B1 (en) | 2008-12-24 |
| DK1805169T3 (da) | 2009-03-16 |
| US7846950B2 (en) | 2010-12-07 |
| DE602005011988D1 (de) | 2009-02-05 |
| ES2318565T3 (es) | 2009-05-01 |
| ATE418553T1 (de) | 2009-01-15 |
| WO2006044228A1 (en) | 2006-04-27 |
| PT1805169E (pt) | 2009-02-16 |
| JP5057982B2 (ja) | 2012-10-24 |
| CY1110453T1 (el) | 2015-04-29 |
| JP2008516952A (ja) | 2008-05-22 |
| US20080015235A1 (en) | 2008-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
| IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
| BRPI0514553A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| DK1957484T3 (da) | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| MY154591A (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| WO2005082893A3 (en) | Histamine h3 receptor antagonists, preparation and therapeutic uses | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| CY1110453T1 (el) | Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| MY148084A (en) | Substituted carboxamides as group i metabotropic receptor antagonists | |
| MX385316B (es) | Compuestos de morfinano. | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| WO2004026837A3 (en) | Histamine h3 receptor antagonists, preparaton and therapeutic uses | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung | |
| EA015500B9 (ru) | Новые антагонисты мсн рецепторов |